Expertise in
1
conditions

David Szwajcer

Winnipeg, MB, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Winnipeg, MB, CA 

Overview

David Szwajcer practices practicing medicine in Winnipeg, Canada.

Mr. Szwajcer is highly rated in 1 condition, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Febrile Neutropenia, Leukemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Winnipeg, MB, Canada
Other Locations
Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: June 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 01, 2025
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units
Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units
Enrollment Status: Completed
Publish Date: April 17, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 2 Less Clinical Trial

35 Total Publications

Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.
Journal: Transplantation and cellular therapy
Published: April 17, 2023

Frequently Asked Questions about David Szwajcer

Is David Szwajcer a top-rated expert for Chronic Graft Versus Host Disease (cGvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. David Szwajcer is classified as an Advanced expert for Chronic Graft Versus Host Disease (cGvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does David Szwajcer participate in research or clinical trials?

Yes. David Szwajcer has published 35 articles and abstracts on conditions like Chronic Graft Versus Host Disease (cGvHD). You can view a list of David Szwajcer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Szwajcer's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile